236 related articles for article (PubMed ID: 35036073)
1. Innate-like NKp30
Correia MP; Stojanovic A; Wels WS; Cerwenka A
Oncoimmunology; 2021; 10(1):1973783. PubMed ID: 35036073
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
3. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.
Butler SE; Brog RA; Chang CH; Sentman CL; Huang YH; Ackerman ME
Cancer Immunol Immunother; 2022 Jan; 71(1):165-176. PubMed ID: 34046711
[TBL] [Abstract][Full Text] [Related]
4. Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells.
Quiros-Fernandez I; Libório-Ramos S; Leifert L; Schönfelder B; Vlodavsky I; Cid-Arregui A
J Med Virol; 2024 May; 96(5):e29630. PubMed ID: 38659368
[TBL] [Abstract][Full Text] [Related]
5. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
7. A TCR-based Chimeric Antigen Receptor.
Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
[TBL] [Abstract][Full Text] [Related]
8. A new therapeutic potential for cancers: One CAR with 2 different engines!
Sheikhi A; Jafarzadeh A
Hum Vaccin Immunother; 2017 Aug; 13(8):1786-1788. PubMed ID: 28494200
[TBL] [Abstract][Full Text] [Related]
9. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs.
Anikeeva N; Panteleev S; Mazzanti NW; Terai M; Sato T; Sykulev Y
J Biol Chem; 2021 Sep; 297(3):101033. PubMed ID: 34371020
[TBL] [Abstract][Full Text] [Related]
10. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
11. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
Karahan ZS; Aras M; Sütlü T
Turk J Haematol; 2023 Feb; 40(1):1-10. PubMed ID: 36719099
[TBL] [Abstract][Full Text] [Related]
12. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
Zhang T; Wu MR; Sentman CL
J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
[TBL] [Abstract][Full Text] [Related]
13. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
[TBL] [Abstract][Full Text] [Related]
14. Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy.
Dogan M; Karhan E; Kozhaya L; Placek L; Chen X; Yigit M; Unutmaz D
J Immunol; 2022 Oct; 209(8):1523-1531. PubMed ID: 36165183
[TBL] [Abstract][Full Text] [Related]
15. Distinct human circulating NKp30
Correia MP; Stojanovic A; Bauer K; Juraeva D; Tykocinski LO; Lorenz HM; Brors B; Cerwenka A
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):E5980-E5989. PubMed ID: 29895693
[TBL] [Abstract][Full Text] [Related]
16. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS
Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995
[TBL] [Abstract][Full Text] [Related]
17. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.
Bashiri Dezfouli A; Yazdi M; Pockley AG; Khosravi M; Kobold S; Wagner E; Multhoff G
Cells; 2021 Dec; 10(12):. PubMed ID: 34943898
[TBL] [Abstract][Full Text] [Related]
18. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
20. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]